Press release
Adalimumab Biosimilar Market to Witness Strong Growth Driven by Autoimmune Disease Cases
Global Adalimumab Biosimilar Market
Global Adalimumab Biosimilar Market Size is estimated to grow at the CAGR of 23.0% during the forecast period for 2025-2034.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1058
A biosimilar is a biologic medical product that closely resembles an already approved reference biologic in terms of safety, purity, and efficacy. One notable example is Adalimumab, a human monoclonal antibody first approved by the U.S. Food and Drug Administration (FDA) in December 2002. Marketed under brand names such as Humira and Exemptia, Adalimumab is a prescription medication used to treat a range of inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, psoriasis, and ulcerative colitis. It functions by binding to tumor necrosis factor-alpha (TNF-α), a cytokine that triggers inflammatory responses implicated in autoimmune diseases. By inhibiting the interaction of TNF-α with its receptors, Adalimumab helps reduce inflammation and associated symptoms.
The global market for Adalimumab biosimilars is projected to experience robust growth over the forecast period. This expansion is primarily attributed to the rising global prevalence of arthritis and dermatological disorders, both of which contribute to increased demand for effective immunomodulatory treatments. According to the World Health Organization (WHO), skin conditions are among the leading causes of health-related disabilities worldwide, affecting over 900 million people at any given time. Many of these conditions, such as eczema, result in chronic symptoms and long-term physical and psychosocial burdens, making them a focal point for healthcare intervention. As such, Adalimumab biosimilars present a promising therapeutic option, particularly in the treatment of chronic skin disorders, and are expected to significantly contribute to market growth.
Furthermore, the introduction of new Adalimumab biosimilars is anticipated to drive down drug prices globally, thereby enhancing accessibility and stimulating demand. This trend is expected to positively impact market expansion throughout the forecast period.
Regionally, North America is projected to maintain a leading position in the Adalimumab biosimilar market, supported by the high prevalence of autoimmune disorders and substantial healthcare expenditures. According to the American Autoimmune Related Diseases Association, over 50 million individuals in the United States are affected by autoimmune diseases, incurring annual treatment costs approaching USD 100 billion. The region's ageing population and advanced healthcare infrastructure are also key contributors to market dominance.
Meanwhile, the Asia-Pacific region is expected to witness significant growth, driven by increasing geriatric demographics, growing pharmaceutical investments from both public and private sectors, and enhanced focus on medical research. These factors collectively position the region as a major growth area for the Adalimumab biosimilar market in the years ahead.
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02
Major market players operating in the Adalimumab Biosimilar market include
Amgen, Pfizer, Celltrion Healthcare Co., Ltd., Sandoz International GmbH, LG Life Sciences, Mochida Pharmaceutical, Fresenius Kabi, Kyowa Hakko Kirin, and Momenta Pharmaceuticals.
Recent collaborations and agreements in the market:
• In June 2022, Sandoz stated that the European Medicines Agency (EMA) has accepted for regulatory consideration the application for high concentration formulation 100 mg/mL (HCF) of its biosimilar Hyrimoz® (adalimumab). All indications covered by the reference medicine* are included in the application, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and uveitis.
• In April 2022, Celltrion Healthcare Canada Limited announced the introduction of Yuflyma®, a biosimilar of Humira® that is high-concentration (100 mg/mL), low-volume, citrate-free, and latex-free (adalimumab). Yuflyma® is a biosimilar of Humira® containing adalimumab with a high-concentration, low-volume, and citrate-free formulation. Celltrion Healthcare Canada Limited continues to be devoted to a patient-centric strategy in order to assure access to novel, high-quality biologics in Canada.
• In Feb 2022, Pfizer Inc. announced that the FDA has accepted the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADATM (adalimumab-afzb) as an interchangeable biosimilar to Humira® for evaluation (adalimumab). Positive topline results from the REFLECTIONS B538-12 trial, which investigated numerous switches between ABRILADA and its reference medication, Humira, both of which were taken with methotrexate in adult patients with moderate to severe rheumatoid arthritis, backed up the PAS (RA).
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1058
Market Segments
Global Adalimumab Biosimilar Market, by Application, 2022-2030 (Value US$ Mn)
• Rheumatoid Arthritis
• Juvenile Idiopathic Arthritis
• Psoriatic Arthritis
• Crohn's Disease
• Ankylosing Spondylitis
• Ulcerative Colitis
• Psoriasis
Global Adalimumab Biosimilar Market, by Distribution Channel, 2022-2030 (Value US$ Mn)
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Other Direct Distribution Channels
Global Adalimumab Biosimilar Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Adalimumab Biosimilar Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Adalimumab Biosimilar Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Adalimumab Biosimilar Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Adalimumab Biosimilar Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Adalimumab Biosimilar Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa
Why should buy this report:
To receive a comprehensive analysis of the prospects for the global Adalimumab Biosimilar market
To receive an industry overview and future trends of the Adalimumab Biosimilar market
To analyze the Adalimumab Biosimilar market drivers and challenges
To get information on the Adalimumab Biosimilar market value (US$Mn) forecast to 2030
Significant investments, mergers & acquisitions in the Adalimumab Biosimilar market industry
Read Overview Report- https://www.insightaceanalytic.com/report/global-adalimumab-biosimilar-market/1058
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Adalimumab Biosimilar Market to Witness Strong Growth Driven by Autoimmune Disease Cases here
News-ID: 4100601 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
4PL Logistics Market Revenue Report with Forecast to 2034
"4PL Logistics Market" in terms of revenue was estimated to be worth $59.6 Billion in 2024 and is poised to reach $133.3 Billion by 2034, growing at a CAGR of 8.5% from 2025 to 2034 according to a new report by InsightAce Analytic.
Get Free Sample Report @
https://www.insightaceanalytic.com/request-sample/1609
Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the global 4PL Logistics Market are:
• Rapid growth of automotive the…
Heavy-Duty Autonomous Vehicle Market Exclusive Trends Analysis with Forecast to …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Heavy-Duty Autonomous Vehicle Market- (By Application (Logistics, Public Transportation, Construction and Mining, Others), By Propulsion Type (Internal Combustion Engine Vehicles, Electric Vehicles), By Vehicle Type (Heavy Trucks, Heavy Buses, Roboshuttles), By Level of Autonomy (Fully Autonomous Vehicles, Semi-Autonomous Vehicles), By Sensor Type (LiDAR, RADAR, Camera, Others)) Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According…
E-Commerce Logistics Market Exclusive Report with Detailed Study Analysis
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global E-Commerce Logistics Market Size, Share & Trends Analysis Report By Service Type (Transportation And Warehousing) And Operational Area (International And Domestic)- Market Outlook And Industry Analysis 2034"
The global e-commerce logistics market is estimated to reach over USD 5340.2 billion by 2034, exhibiting a CAGR of 26.4% during the forecast period.
Request For Free Sample Pages:…
E-bikes Market Exclusive Report on the Latest Revenue and Future Scope
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global E-bikes Market Size, Share & Trends Analysis Report By Class (Class-I, Class-II, Class-III), Speed (Up to 25km/h, 25-45 km/h), Battery Type (Lithium-ion, Lithium-ion Polymer, Lead Acid), Mode (Pedal Assist, Throttle), Component (batteries, electric motors, frames with forks, wheels, crank gears, brake systems and motor controllers) , Motor Type (hub and mid), Usage (mountain, trekking, city/urban,…
More Releases for Adalimumab
Adalimumab Biosimilar Market Report and Forecast 2024-2032
Global Adalimumab Biosimilar Market Outlook
The adalimumab biosimilar market is expected to grow at a CAGR of about 17.60% in the forecast period of 2024-2032, driven by the rising incidence of rheumatoid arthritis, especially amongst the rapidly growing geriatric population.
Adalimumab Biosimilar: Introduction
Adalimumab biosimilars are biologic medical products highly similar to the reference product, Humira, which is used to treat autoimmune diseases. These biosimilars offer comparable efficacy, safety, and quality at a…
Adalimumab Biosimilar Market Size, Share, Trends 2024-2032
The adalimumab biosimilar market is witnessing substantial growth, driven by the rising incidence of rheumatoid arthritis and an increasing geriatric population. Adalimumab, a popular biologic for treating various inflammatory diseases, has seen a surge in biosimilar counterparts due to their cost-effectiveness and expanding applications. The market is expected to grow at a CAGR of about 17.60% from 2024-2032, reflecting significant opportunities for industry players.
Get a Free Sample Report with Table…
Adalimumab Market Insights, Forecast to 2031
"Adalimumab Market 2024,"
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Adalimumab market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Adalimumab industry, providing stakeholders with a nuanced perspective on market dynamics.
Furthermore, the…
Adalimumab Market Size, Status & Forecast 2024
Global Adalimumab Market: Overview
Adalimumab, with a trade name of Humira and Exemptia, is an anti-TNF drug used for treating rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, psoriasis and ulcerative colitis. Adalimumab usually binds with tumor necrosis factor-alpha (TNFα). When a TNFα binds to a TBFα receptors, it results in an inflammatory response to autoimmune disease. Adalimumab, by binding to a TNFα, lowers the chances of inflammatory response.
View Report @ http://www.transparencymarketresearch.com/adalimumab-market.html
Adalimumab, which…
Adalimumab Market - Forecasts from 2014 to 2020
Adalimumab is a biologic TNF inhibiting anti-inflammatory medication which is a patented medicine of Abbott Biotechnology Ltd. Jochen G. Salfeld et al invented the product and trade names for the product are Exemptia and Humira. Humira stands for "human monoclonal antibody in rheumatoid arthritis". Humira targets and acts as building block for TNF-alpha production, and lowering inflammation. TNF blockers with HUMIRA, has adverse affects on the immune system which…
Increasing Research and Penetration of Adalimumab Biosimilars Boosts Demand for …
The impending patent expiration has resulted in the sluggish growth rate of the adalimumab market in Latin America. The entry of biosimilars has further aggravated the market’s concerns. Transparency Market Research (TMR) pegs the valuation of the Latin America adalimumab market at US$994.8 mn in 2014. Expanding at a weak CAGR of 0.4% from 2015 to 2023, the market is forecast to reach US$1,186.4 mn by the end of 2023.
Download…
